Physician profile
Christopher Stallter
NPI 1134115629
$10,692.33
in general payments reported to CMS, 2019-2025
48 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $1,192 · 2021: $1,339 · 2022: $1,774 · 2023: $2,312 · 2024: $1,961 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,631.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.02 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,062.50 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Lilly USA, LLC | $1,035.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,003.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $983.74 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $883.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $868.80 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $404.45 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $335.83 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $292.36 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.99 | 2019-2024 | Xifaxan |
| Allergan, INC. | $210.89 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.11 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $179.62 | 2019-2022 | |
| Sanofi Pasteur INC. | $178.04 | 2019-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stallter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.